Overview

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), is currently being studied in a Phase 1/2 clinical trial for the treatment of recurrent, metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

 

Latest Presentation

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

04 Jan '2022
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the 40 th Annual J.P.

Events & Presentations

SEC Filings

Filing date Description Form

Notice of Exempt Offering of Securities

D

Notice of Exempt Offering of Securities

D

Amendment to a previously filed Notice of Exempt Offering of Securities

D/A